Floatz logo

(+)-VINCRISTINE

Malignant Ovarian Epithelial Tumor

Mayo ClinicSmall moleculePhase 2Dormant
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
48/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Malignant Ovarian Epithelial Tumor cohort.

Asset / SponsorPhaseRating
Irinotecan
Mayo Clinic
Phase 2BB
Cediranib
Mayo Clinic
Phase 1CC
Dordaviprone
Ira Winer
Phase 2CC

Same molecule, other indications

(+)-VINCRISTINE is also rated in:

anaplastic large cell lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →